The study confirmed that a fully depleted function of PARP1 has a merely moderate effect in TMEJ disruption, which may help to understand why double inhibition of Polθ and PARP has a greater impact in the treatment of HR-deficient cancer cells [24]. The gene discussed is PARP1; the disease is cancer.